May 22, 2009 - New data presented yesterday at EuroPCR from an international, post-approval, single-arm study show that Abbott's XIENCE V Everolimus Eluting Coronary Stent System demonstrated low rates of repeat procedure (target lesion revascularization), stent thrombosis and major adverse cardiac events (MACE) in a complex patient population.
